ǰÑÔ
´¹ÌåÁö(pituitary tumor)ÊÇÒ»ÖÖ³£¼ûµÄÂÄÚÖ×Áö£¬Ô¼Õ¼ÂÄÚÖ×ÁöµÄ10%~15%¡£´¹Ìå¿É·Ö³É´¹ÌåǰҶ£¨ÏÙ´¹Ì壩ºÍ´¹ÌåºóÒ¶£¨Éñ¾´¹Ì壩Á½´ó²¿·Ö¡£´¹ÌåǰҶϸ°ûÉøÍ¸ÃÚÈéËØ(prolactin,PRL)¡¢´ÙÉöÉÏÏÙÆ¤Öʼ¤ËØ(adrenocorticotropic hormone,ACTH)¡¢ÂÑÅݴ̼¤ËØ(follicle stimulating hormone,FSH)ºÍÐþɫϸ°û´Ì¼¤ËØ(melanocyte stimulating hormone,MSH)µÈ¡£Éñ¾´¹Ìå×Ô¼º²»ÖÆÔì¼¤ËØ£¬¶øÊÇÆðÒ»¸ö¿ÍÕ»µÄ×÷Óá£ÏÂÇðÄÔµÄÊÓÉϺ˺ÍÊÒÅÔºËÌìÉúµÄ¿¹ÀûÄò¼¤Ëغʹ߲úËØ£¬Í¨¹ýÏÂÇðÄÔÓë´¹ÌåÖ®¼äµÄÉñ¾ÏËά±»Ë͵½Éñ¾´¹ÌåÖü´æÆðÀ´£¬µ±ÉíÌåÐèҪʱ¾ÍÊͷŵ½ÑªÒºÖС£
´¹ÌåÁöÒÔǰҶµÄÏÙÁöÕ¼´ó´ó¶¼£¬À´×ÔºóÒ¶ÕßÉÙ¼û¡£´¹ÌåÁöµÄÖ¢×´ÌåÕ÷Ö÷ÒªÊÇÓÉÓÚÖ×ÁöµÄ¾Ö²¿Õ¥È¡£¬»ò¼¤ËØÉøÍ¸¹ý¶à£¬»òÒòÖÎÁÆÒýÆðµÄ¼¤ËØÉøÍ¸È±·¦¶øÌåÏÖ³öһϵÁеÄÁÙ´²ÌåÏÖ¡£Ö×Áöեȡ´¹ÌåÖÜΧ×éÖ¯ÌåÏÖΪһÁ¬ÐÔÍ·Í´£¬ÊÓ½»Ö¯¼°ÊÓÉñ¾ÊøÕ¥È¡Ö¢£¬·ºÆðÊÓÁ¦¼õÍË¡¢ÊÓҰȱËðºÍÑ۵׸ıäµÈ¡£¼¤ËØÉøÍ¸Òì³£ÌåÏÖΪ¹¦Ð§ÐÔÖ×Áöϸ°ûÉøÍ¸¹ý¶à¼¤ËØ£¬ÈçÉú³¤¼¤Ëعý¶àÒýÆðÖ«¶Ë·Ê´óÖ¢£¬»òÎÞ¹¦Ð§ÐÔÖ×ÁöÔö´ó£¬ÆÆËðÕý³£´¹Ìå×é֯ʱÒýÆð¼¤ËØÉøÍ¸¹ýÉÙ£¬Èç´ÙÐÔÏÙ¼¤ËØÉøÍ¸ïÔ̶ø±Õ¾¡¢²»Óý»òÑôήµÈ¡£
´¹ÌåÁö¶¯ÎïÄ£×Ó¿É·ÖΪÓÕ·¢ÐÔ´¹ÌåÁöÄ£×Ó¡¢×Ô¾õÐÔ´¹ÌåÁöÄ£×Ó¡¢ÒÆÖ²ÐÔ´¹ÌåÁöÄ£×ÓÒÔ¼°»ùÒòÐÞÊδ¹ÌåÁöÄ£×ÓËÄÀà¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯Î´óÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
ºã¾ÃÓôƼ¤Ëش̼¤¿ÉÓÕµ¼´óÊ󱬷¢´¹ÌåPRLÁö£¬ÆäÏêϸ»úÖÆÉÐδÍêÈ«Ã÷Îú¡£ÓÕµ¼ÀÖ³ÉÓë·ñÓëÆ·ÏµÓйأ¬ÈçF344´óÊó½ÓÊܺã¾Ã´Æ¼¤ËØ£¬¼¸ÖܺóÆäÏÙÌåÒì³£ÔöÌí³ÉÁö£¬Ìå»ý¿É´ïÕý³£´¹ÌåµÄ10~20±¶¡£ÆäËûÃô¸ÐµÄ´óÊóƷϵÉÐÓÐAxCIrish (ACI)¡¢Wistar-FurthºÍCopenhagen (COP)µÈ£»¶øHoltzman¡¢Sprague DawleyºÍBrown-Nonvay´óÊóºã¾Ã¸øÓè´Æ¼¤ËØºó£¬Æä´¹Ìå¾ÞϸÈÔά³ÖÕý³£¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
È¡Wistar-Furth´óÊó£¬ÌåÖØ60~80g£¬êòĵ²»¾Ð¡£¼ºÏ©´Æ·Ó(diethylstilbestrol,DES)ÈÜÓÚÎÞ¾ú»¨ÉúÓÍÖУ¬ÊµÑé×鸹ǻÄÚ×¢Éä5mg/kg DESÒõÐÔ±ÈÕÕ×é×¢ÉäµÈÁ¿»¨ÉúÓÍ£¬Õý³£±ÈÕÕ×é½ö´©´Ì²»×¢É䣬2´Î£¯ÖÜ¡£»®·ÖÓÚ4¡¢8¼°12ÖÜËæ»úÕý·¨¡£È¡ÑªÇåÓ÷ÅÉäÃâÒ߯ÊÎö·¨²âPRL£¬È¡´¹Ì峯֨£¬×ö×éÖ¯²¡ÀíѧºÍÃâÒß×黯¼ì²é¡£
¡¾Ä£×ÓÌØµã¡¿£º
¸øÓ輺ϩ´Æ·ÓµÄ´óÊó£¬8ÖÜÒÔºó´¹Ì寽¾ùÖØÁ¿¼°ÑªÇåPRL½ÏÒõÐÔ±ÈÕÕ×éÏÔ×ÅÉý¸ß£»¹â¾µÏÂH&EȾɫ¼ûϸ°ûÊýÄ¿Ôö¶àÏÔ×Å£¬Ï¸°û³ÊÔ²Ðλò¶à½ÇÐΣ¬°ûÖÊ´øÔö¿í£¬ºË¾Þϸ·×Æç£¬ÉîȾ£¬ÓкËÒìÐÍÐÔ£¬Ö×Áö³äѪ²¢¿É¼ûÐÂÉúѪ¹Ü£¬ÏÙ¹ÜÑù½á¹¹³Ê×ÜÌåÏûÊÅ״̬¡£µÚ12ÖÜ100£¥·ºÆðÁöÑù¸Ä±ä£¬´¹Ìå½ÏÒõÐÔ±ÈÕÕ×éÏÔÖøÔö´ó£¬²¢¿É¼ûÁöÄÚ³öѪÌåÏÖ¡£
¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º
ÓôƼ¤ËØÓÕ·¢ÐÔ´¹ÌåÁö¾ßÓÐÒÔÏÂÌØµã£º¢ÙÓÕ·¢ÁöµÄ±¬·¢ÂÊÓëÒÅ´«Óйأ¬ÓÐЩƷϵÓÕ·¢Âʺܸߣ¬¶øÁíһЩȴºÜµÍ¡£ÈçF344´óÊóµÄÓÕ·¢ÂÊΪ100%£¬¶øHoltzman´óÊóµÄÓÕ·¢ÂÊΪ2%¡«6%£»¢Ú¾ßÓдƼ¤ËØÒÀÀµÐÔ¡£Ëæ×ŴƼ¤ËصĴýÐøÓ¦Ó㬴¹ÌåÓÉÔöÉúÐԸı䵽Ö×ÁöÐԸı䣬ͣÓôƼ¤Ëغó£¬ÓÕ·¢µÄÖ×ÁöÖð½¥ËõСÉõÖÁÏûÊÅ¡£Òò´ËһЩѧÕßÒÔΪ£¬´Æ¼¤ËØ´¦Öóͷ£µÄ´óÊó´¹Ìå¸Ä±ä´ó´ó¶¼ÊÇÔöÉúÐÔ¸Ä±ä¶ø²»ÊÇÖ×ÁöÐγɡ£Ôµ¹ÊÔÓÉÊÇ£º¢Ù´Æ¼¤ËØÓÕ·¢µÄ“Ö×Áö”²»¿É±»ÒÆÖ²µ½Ã»Óо´Æ¼¤ËØ´¦Öóͷ£µÄ´óÊóÉíÉÏ£»¢ÚÍ£ÓôƼ¤Ëغ󣬴¹ÌåµÄÖØÁ¿¼±¾çϽµÖÁ»Ö¸´Õý³£¡£µ«Ä³Ð©ÓÕ·¢µÄÖ×ÁöÉú³¤µ½Ò»¶¨½×¶Î£¬Ò²¿É²»ÒÀÀµ´Æ¼¤Ëضø¼ÌÐøÉú³¤¡£
´Æ¼¤ËØÓÕ·¢ÐÔ´¹ÌåÁö¶¯ÎïÄ£×ÓÖÆ×÷¼òÆÓ£¬ÓëÈËÀàPRLÁöÏàËÆ£¬ÔÚ´¹ÌåPRLÁöµÄ»ù´¡ºÍÁÙ´²Ñо¿ÖлñµÃÆÕ±éÓ¦ÓᣴËÄ£×Ó¿ÉÓÃÓÚÑо¿´¹ÌåÁö²¡Òò¡¢·¢²¡»úÖÆ¡¢ÁÙ´²ÖÎÁÆÒÔ¼°Ò©ÎïµÄÑз¢¡£
²Î¿¼ÎÄÏ×£º
1.ÕÅÃÍ£¬ÕÅÇïÉú£¬ÁÖºãÖÝ£¬µÈ. ÒÒÏ©´Æ·ÓÓÕµ¼µÄ´óÊó´¹ÌåÁöÄ£×ӵĽ¨É裮Öйú²¡ÀíÐÄÀíÔÓÖ¾£¬2012, 28 (8): 1532-1536
2.Helseth A, Siegal GP, Haug E, et al Transgenic mice that develop pituitary tumors. A model for Cushing's disease£®Am J Pathol, 1992, 140 (5):1071-1080
3.Cristina C, Garc í a-Tornad ú I, D í az-Torga G, et al.Doparninergic 02 receptor knockout mouse: an animal model of prolactinoma. Front Horm Res, 2006, 35: 50-63
4.Ishii J, Kawakami Y. Recent progress in experimental pituitary tumors in various animals. Nihon Rinsho, 1993, 51 (10):2580-2584
5.Fedele M, Battista S, Kenyon L, et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene,2002,21 (20):3190-3198
6.Pernasetti F, Spacly TJ, Hall SB,et al. Pituitary turnorigenesi targeted by the ovine follicle-stimulating hormone betasubunit gene regulatory region in transgenic mice. Mol Cell Endocrinol, 2003,203 (1-2): 169-183